Immunotherapies have been hot topics at the last two ASH and ASCO conferences. That trend didn’t let up at this year’s American Society of Hematology annual meeting in New Orleans.
New targeted therapy options headlined this year’s American Society of Hematology meetings in New Orleans this year. One example: new drugs for chronic lymphocytic leukemia (CLL) that are more effective and better tolerated.
So much cancer related news I don’t know where to start. ASH started on Friday and continues this week. ASH stands for “American Society of Hematology,” and the annual meeting rotates among a half dozen southern convention venues large enough close to 30,000 researchers, nurses, doctors and drug company staffers. This makes ASH the largest gathering of hematologists in the world.
I just started a two part series about kelp and it’s anti-cancer properties on my daily MultipleMyelomaBlog.com site:
As promised yesterday, here is an excerpt from a New York Times/Tampa Bay Times article about this year’s blockbuster therapy breakthrough at ASH in Atlanta:
I spent last weekend covering the American Society of Hematology (ASH) annual meetings in Atlanta. ASH is the largest gathering of hematologists in the world each December.
Chord blood transplants can be effective and are growing in popularity for use against a variety of blood cancers. I saw this study abstract in Saturday’s media packet. Glad journalist Raxanne Nelson followed-up on the story:
Double Cord Blood Transplant Better Than Single in Leukemia
December 5, 2010 (Orlando, Florida) — A double cord blood transplant (CBT) is not only feasible but also appears to be associated with better overall outcomes than a single CBT, according to new data presented here at the American Society of Hematology 52nd Annual Meeting. This was found to be particularly true when used early in the treatment of acute leukemias.
I recently ran an article about a promising new lymphoma drug, brentuximab vedotin (SGN-35). Here are study results, just released to us from the ASH press room about bv:
Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma [Abstract 283]
While 70-80 percent of all newly diagnosed patients with adult Hodgkin lymphoma are typically cured with combination chemotherapy of three or four agents together, there still is a significant number of patients whose disease progresses after initial induction chemotherapy. For these patients, treatment options include additional courses of the same or different chemotherapy regimens followed by an autologous stem cell transplant. However, for patients whose disease returns after an autologous stem cell transplant, there currently are no approved treatment options.
Since Help With Cancer.org is a general information site, I have decided not to flood our pages with too many specific abstracts or study results from here at ASH unless they are truly significant. Here is a general leukemia related release which summarizes the impact from some of today’s research study data:
I just finished a brief review of the first poster sessions this afternoon. Close to one hundred posters, all displaying research results for blood related cancers and other disorders.
Here is some important info, and good news, for kids with leukemia that have relapsed from here at ASH:
ASH: Regimen Ups Survival in Relapsed ALL in Kids
By Charles Bankhead, Staff Writer, MedPage Today
Hello from ASH in Orlando! The first press releases and research study results from the meetings will be available later today. In the meantime, here is an interesting article about the value of acupuncture I wanted you to see:
I have been writing a lot about the upcoming American Society of Hematologists (ASH) annual meeting on our other daily site, http://www.multiplemyelomablog.com/.
Millennium, a division of the Takeda Oncology Company in Japan, is a leading biopharmaceutical company based in Cambridge, Massachuesets. Millenium markets VELCADE, a proteasome inhibitor which is primarily used in multiple myeloma patients.
News from last month’s ASH conference in New Orleans continues to trickle-out. (or should it be “trickle-in?) I found this article interesting about a new standard of care for Hodgkin’s lymphoma:
That’s a mouthful, isn’t it! I normally don’t get this technical on this www.HelpWithCancer.Org site, but friends e-mailed me a comprehensive report from ASH I thought some of you might be interested in. Here is an excerpt:
I got so busy I forgot to post this Vitamin D news from ASH:
Here is some good news for patients with chronic leukemia,courtesy of ScienceNews.Org from ASH:
I was traveling this evening, but based on the data I reviewed in person and on-line the last three days at ASH, the blockbuster news I was told to expect has yet to materialize. I see a few promising Stage I studies and even fewer Stage II studies. Like myeloma, drug combinations are being tried every which way. Another trend is using successful myeloma drugs against certain types of lymphoma and leukemia. You can Google ASH and leukemia and/or lymphoma, but be prepared to be underwhelmed! I will follow-up tomorrow.
I just stopped-in to a clinical session about leukemia here at ASH. My focus, and actually, the largest focus here in New Orleans, is multiple myeloma. But watch for exciting news over the next few days about new drugs and drug combinations for leukemia and lymphoma.